These deals are certainly within the letter of the law but run counter to its spirit and intention of promoting competition between generic companies and aggressive challenges to branded company patents.
详情正文
登录后查看完整内容
使用 DeepEvidence / 梅斯账号登录，新用户可在登录页面注册。
登录 / 注册登录成功后将返回当前页面，继续浏览。